Human Phospho-PGC1 alpha (S571) Antibody

Detection of Human Phospho-PGC1 alpha (S571) by Western Blot.

Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line and Jurkat human acute T cell leukemia cell line untreated (-) or treated (+) with 10 nm Recombinant Human IGF-I (Catalog # 291-G1) for 1 hour. PVDF Membrane was probed with 1 µg/mL of Rabbit Anti-Human Phospho-PGC1a (S571) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6650) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for Phospho-PGC1a (S571) at approximately 120 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Detection of Phospho-PGC1 alpha (S571) by Western Blot

Expression levels of mitochondrial biogenesis proteins in control and mutant cells with and without treatment. Polydatin and nicotinamide at 10 µM were used for seven days. (A) Immunoblotting analysis of mitochondrial biogenesis proteins in control (C1, C2) and mutant (P1, P2) cells. Actin was used as the loading control. (B) Band densitometry of Western blot data referred to actin and normalized to the mean of controls. (C) Immunoblotting analysis of mitochondrial biogenesis proteins in control (C1, C3) and mutant (P3) fibroblasts. Actin was used as the loading control. Original images can be found in Supplementary Materials. (D) Band densitometry of Western blot data referred to actin and normalized to the mean of controls. Data represent the mean ± SEM of three independent experiments. **** p < 0.0001 between control and GFM1 fibroblasts. ####p < 0.0001 between untreated and treated GFM1 cells. a.u.: arbitrary units. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38786005), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Phospho-PGC1 alpha (S571) by Western Blot

VEGFR2 inhibition by Ki8751 interferes VEGF intracellular signaling in glioblastoma cells. A Western blot images showing the protein levels of p-VEGFR2, VEGFR2, p-PGC1 alpha, PGC1 alpha, p-AKT, AKT, TFAM of U38 cell in the absence or presence of Ki8751treatment for 48 h. The bar graphs plot the relative intensities of p-Akt and p-PGC1 alpha. Mean ± SEM, ***p < 0.001, ****p < 0.0001 as compared to vehicle treatment. B Western blot images of p-PGC1 alpha, PGC1 alpha, p-AKT, AKT, and TFAM immunoreactive bands of U38 cells with VEGFR2 knockdown by shRNAs. Mean ± SEM, ****p < 0.0001 as compared to the control shSCR. C Immunofluorescence images demonstrate the cellular location of PGC1 alpha staining in U38 and U87 cells without or with Ki8751 treatment for 48 h. DAPI was used as a nuclear location marker. Bar charts depict PGC1 alpha fluorescence intensities without or with Ki8751 treatment. Mean ± SEM, *p < 0.05 as compared to vehicle, n = 3. D Western blot images showing the protein level of PGC1 alpha in the cytosol and nucleus of U87 cells after treatment with Ki8751 or shRNA knockdown. LaminB1 and GAPDH were used as input control for nuclear protein or cytoplasmic protein, respectively. Bar graphs show the relative expression of nuclear PGC1 alpha in U87 cells. Mean ± SEM, ****p < 0.0001 as compared to the control. E Schematic illustration of VEGFR2 inhibition-induced mitochondrial biogenesis signaling and apoptosis in glioblastoma cells Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38702818), licensed under a CC-BY license. Not internally tested by R&D Systems.